Regenxbio公布关键性III期AFFINITY Duchenne®研究中RGX-202的积极顶线结果

美股速递
May 14

生物技术公司Regenxbio Inc宣布,其针对杜氏肌营养不良症(DMD)的研究性基因疗法RGX-202,在关键性III期AFFINITY Duchenne®研究中取得了积极的顶线结果。

数据显示,该疗法达到了研究的主要终点,在患者运动功能的关键评估指标上表现出具有统计学意义和临床意义的改善。安全性方面,RGX-202的耐受性普遍良好,观察到的不良事件与先前研究一致。

这一积极结果为RGX-202的后续监管申请奠定了坚实基础。公司计划基于这些数据,与全球监管机构进行讨论,以推动该疗法早日惠及DMD患者。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10